FDA’s highly popular “breakthrough therapy” program may still be at a young age, but sponsors who have successfully navigated the expedited pathway to drug approval believe some changes could help it function more effectively.
During a May 6 briefing sponsored by Friends of Cancer Research, representatives from Pharmacyclics Inc. and Genentech Inc....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?